Navigation Links
Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
Date:3/4/2008

XYOTAX to be reviewed for PS2 first-line non-small cell lung cancer

indication

SEATTLE, March 4 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for XYOTAX(TM) (paclitaxel poliglumex, CT-2103) for first-line treatment of patients with non-small cell lung cancer (NSCLC) who have ECOG (Eastern Cooperative Oncology Group) performance status 2 (PS2). The application is based on a positive opinion CTI received from the EMEA's Scientific Advice Working Party, which agreed to review the application based on the existing results of the phase III clinical trials of XYOTAX, known as the STELLAR trials.

In the STELLAR 4 trial, single-agent XYOTAX resulted in comparable survival to gemcitabine or vinorelbine in first-line patients and, with the exception of neuropathy known to be associated with taxane therapy, demonstrated significant reduction in several clinically meaningful toxicities, such as severe neutropenia and infection, and in the requirement for transfusions and use of hematopoietic growth factor support. In addition to improved tolerability, XYOTAX offered more convenient administration compared to currently used treatments and a reduction in overall utilization of medical resources compared to gemcitabine or vinorelbine.

The application will be formally reviewed for validation by the end of March. Upon validation, the marketing approval review process begins, which generally takes 15 to 18 months.

"This is an important milestone for CTI and demonstrates our commitment to bring XYOTAX to this underserved group of patients. Currently there are no approved treatments for first-line use in PS2 patients with non-small cell lung cancer. Every day counts when treating patients who may have an average life expectancy of only six months, so quality of life an
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
9. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
10. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
11. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)...  Hologic, Inc. (Hologic or the Company) (NASDAQ: ... and supplier of premium diagnostics, medical imaging systems ... the healthcare needs of women, today announced that ... clinical practice comparing breast cancer screening with Hologic,s ... mammography alone showed a significant reduction in recall ...
(Date:5/23/2013)...   Direct to implant, or "one step," ... option for many women with BRCA (BReast CAncer) ... cancer risk, or with breast cancer. Traditionally, post-mastectomy ... second surgery to insert permanent implants, but immediate ... mastectomy can be a medically and cosmetically effective ...
(Date:5/23/2013)... May 23, 2013  Net Medical Xpress Solutions, Inc., ... announced today the company has signed a letter of ... based in Huntsville, AL . MedTel ... the staffing and recruitment of telemedicine physicians. Consideration for ... final agreement, which is expected by June 30, 2013. ...
Breaking Medicine Technology:First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 2First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 4Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 2Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 3Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 2Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 3
... Target Enrollment Expected in Fourth Quarter, BERKELEY ... GNTA ) announced that the Data Safety Monitoring ... Genasense (oblimersen sodium),Injection, which is the Company,s lead ... as originally planned after initial review of,blinded safety ...
... unique Ranexa(R) mechanism of action -, CHICAGO, March ... today that ranolazine significantly (p<0.001),shortened the QT interval of ... LQT3, which is caused by a genetic mutation in ... rhythm problems, including,sudden death. Ranolazine also shortened cardiac relaxation ...
Cached Medicine Technology:DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma 2DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma 3DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma 4Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder 2Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder 3
(Date:5/25/2013)... May 25, 2013 Dr. Leslie Gerstman ... procedure FDA-approved to lift skin on the neck, on the ... her practice, Medical Aesthetics. , Ultherapy is a non-surgical procedure ... natural healing process to lift the skin over time. The ... time, to see and then treat the deepest support layers ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 Communities of ... Texas. It is the fifth largest media market in the ... the number one visitor destination in Texas and a major ... to the American West as it is home to many ... will enjoy from sports to the arts. Residents and locals ...
(Date:5/25/2013)... -- Many viruses and parasites that affect both dogs ... bacteria-borne illness than can result in liver or kidney ... to a veterinarian. These germs could be ... said Dr. Susan Nelson, a clinical associate professor at ... serious diseases can be fatal, even with treatment," she ...
(Date:5/25/2013)... May 25, 2013 Radius Engineering ... shelter company in the US and has been ... for over 35 years. M.E. and President, Walton ... of NBC Weapon Fundamentals and Shelter Engineering Standards, ... bible on shelter engineering. McCarthy is considered the ...
(Date:5/25/2013)... Absolute Surgical Specialists, serving Sun City Center for ... throughout the country participating in Shop Local for a Cause. ... event as he understands what military families go through after ... said, “I wanted to give something back, as I not ... here too.” , Shop Local for a Cause has chosen ...
Breaking Medicine News(10 mins):Health News:Dr. Leslie Gerstman Is Now Offering the Non-surgical Facelifting Procedure – Ultherapy – in NYC and NJ 2Health News:Communities of Distinction TV Presents May Air Dates for Dallas-Ft. Worth, Texas 2Health News:Hidden Dangers Dog Dog Parks 2Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 2Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 3Health News:Dr. Craig Amshel of Absolute Surgical Specialists Offering Bowel Prep During the Shop Local for a Cause Event 2
... ... series of free 90-minute online classes this month to help returning combat veterans and ... critical for combat veterans and families. , ... (PRWEB) November 12, 2009 -- The nonprofit PAIRS Foundation will ...
... Catholic ... , ... (PRWEB) November 11, 2009 -- Drexel University Online honored Catholic Health East ... to training and development through various forms of eLearning to meet business goals and ...
... ... and design services, Ms. McKenna and the Beyond the Box team can assist seniors and ... , ... -- The Washington, DC based relocation and design firm, Beyond the Box , is ...
... ... core lab market with largest number of highly automated QT(sm) studies. , ... Rochester, NY (PRWEB) November 11, ... and QT analysis, announced today that a top five pharmaceutical company has awarded iCardiac ...
... High levels of workplace exposure to Bisphenol-A may increase the ... Kaiser Permanente study appearing online in the journal Human ... The five-year study examined 634 workers in factories in China, ... of workers in factories where no BPA was present. The ...
... Public Health researchers will present Nov. 11 on a ... annual meeting in Philadelphia, including a study that found ... wellness program. Additional public health research findings ... faith affect how Southern African-American women use contraception? , ...
Cached Medicine News:Health News:PAIRS Foundation Offering Free Classes to Help Combat Veterans Impacted by PTSD 2Health News:PAIRS Foundation Offering Free Classes to Help Combat Veterans Impacted by PTSD 3Health News:Catholic Health East Named 2009 National Distance Learning Week Award Recipient 2Health News:Catholic Health East Named 2009 National Distance Learning Week Award Recipient 3Health News:Relocation Specialists Beyond the Box Team With Nurse to Help Facilitate Senior Moves 2Health News:Relocation Specialists Beyond the Box Team With Nurse to Help Facilitate Senior Moves 3Health News:Top Five International Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac 2Health News:Workplace BPA Exposure Increases Risk of Male Sexual Dysfunction, Kaiser Permanente Study Finds 2Health News:Workplace BPA Exposure Increases Risk of Male Sexual Dysfunction, Kaiser Permanente Study Finds 3Health News:Workplace BPA Exposure Increases Risk of Male Sexual Dysfunction, Kaiser Permanente Study Finds 4Health News:Workplace BPA Exposure Increases Risk of Male Sexual Dysfunction, Kaiser Permanente Study Finds 5Health News:Worksite wellness programs may reduce employee absenteeism 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: